yahoo_financeOriginal article
FDA Alignment to Advance ProstACT Global Phase 3 Trial
Phase 3ProstACTPositive
AI Analysis
Summary
Telix Pharmaceuticals achieved FDA alignment to advance the ProstACT global Phase 3 trial. The company secured FDA feedback on the trial design and regulatory pathway for the prostate cancer treatment candidate.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA alignment meeting to advance global Phase 3 trial
Importance:6/10
Sentiment:
0.50
FDA alignmentPhase 3 trialProstACTprostate cancerregulatory
Related Companies
Read the original article
Published by yahoo_finance on July 2, 2026 1:31 AM